PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 260 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,504 | -15.6% | 374,980 | +10.2% | 0.02% | -9.1% |
| Q2 2023 | $13,631 | +22.0% | 340,169 | +24.2% | 0.02% | +15.8% |
| Q1 2023 | $11,174 | -80.3% | 273,816 | -81.4% | 0.02% | -83.3% |
| Q4 2022 | $56,831 | -99.9% | 1,471,918 | +2.3% | 0.11% | -26.5% |
| Q3 2022 | $76,527,000 | +2.1% | 1,438,741 | +11.9% | 0.16% | +11.5% |
| Q2 2022 | $74,963,000 | -24.1% | 1,285,829 | -0.6% | 0.14% | +5.3% |
| Q1 2022 | $98,736,000 | +37.8% | 1,293,700 | +8.6% | 0.13% | +51.7% |
| Q4 2021 | $71,645,000 | +11.1% | 1,190,714 | +3.4% | 0.09% | +10.1% |
| Q3 2021 | $64,504,000 | -5.6% | 1,151,847 | +2.3% | 0.08% | -4.8% |
| Q2 2021 | $68,338,000 | -13.9% | 1,126,199 | -0.6% | 0.08% | -19.4% |
| Q1 2021 | $79,382,000 | +16.9% | 1,132,583 | -0.2% | 0.10% | +14.4% |
| Q4 2020 | $67,880,000 | +34.1% | 1,134,353 | +34.7% | 0.09% | +21.6% |
| Q3 2020 | $50,627,000 | +16.8% | 842,100 | +1.9% | 0.07% | +5.7% |
| Q2 2020 | $43,352,000 | +71.3% | 826,232 | +9.4% | 0.07% | +34.6% |
| Q1 2020 | $25,315,000 | +6.5% | 754,996 | +43.9% | 0.05% | +30.0% |
| Q4 2019 | $23,764,000 | +18.8% | 524,593 | -0.2% | 0.04% | +2.6% |
| Q3 2019 | $20,004,000 | +1000100.0% | 525,455 | +847408.1% | 0.04% | – |
| Q3 2016 | $2,000 | 0.0% | 62 | 0.0% | 0.00% | – |
| Q2 2016 | $2,000 | -66.7% | 62 | -44.1% | 0.00% | – |
| Q1 2016 | $6,000 | +100.0% | 111 | +200.0% | 0.00% | – |
| Q4 2015 | $3,000 | -100.0% | 37 | -100.0% | 0.00% | -100.0% |
| Q3 2014 | $13,599,000 | -17.4% | 140,309 | -21.7% | 0.04% | -14.9% |
| Q2 2014 | $16,464,000 | -3.0% | 179,231 | -26.1% | 0.05% | -2.1% |
| Q1 2014 | $16,974,000 | +8.0% | 242,516 | -11.3% | 0.05% | +2.1% |
| Q4 2013 | $15,718,000 | -18.1% | 273,415 | -31.5% | 0.05% | -24.2% |
| Q3 2013 | $19,192,000 | +36.5% | 399,084 | -17.7% | 0.06% | +24.0% |
| Q2 2013 | $14,060,000 | – | 484,836 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |